Implantation Site of a Port Delivery System With Ranibizumab: Anterior Segment Optical Coherence Tomography Evaluation

Connor J Ericksen; Cory A Christensen; Brian Berger; Shamika Gune; Jared S Nielsen

doi:10.1177/24741264221105809

Implantation Site of a Port Delivery System With Ranibizumab: Anterior Segment Optical Coherence Tomography Evaluation

J Vitreoretin Dis. 2022 Aug 4;6(5):347-350. doi: 10.1177/24741264221105809. eCollection 2022 Sep-Oct.

Authors

Connor J Ericksen¹, Cory A Christensen², Brian Berger³, Shamika Gune⁴, Jared S Nielsen¹

Affiliations

¹ Vitreoretinal Diseases and Surgery, Wolfe Eye Clinic, West Des Moines, IA, USA.
² Des Moines University, Des Moines, IA, USA.
³ Austin Clinical Research, Austin, TX, USA.
⁴ Genentech Inc, South San Francisco, CA, USA.

Abstract

Purpose: To determine whether anterior segment optical coherence tomography (AS-OCT) can be used to obtain noninvasive high-resolution images for monitoring the implantation site of a port delivery system with ranibizumab (PDS). Methods: Six eyes from the Archway phase 3 trial were imaged with AS-OCT after surgical implantation of the PDS and at regular follow-up visits. Results: AS-OCT was helpful in monitoring the status of the overlying conjunctiva and Tenon capsule after implantation of the PDS. Minimal qualitative thinning was observed over the implants at the longest follow-up. No cases of conjunctival erosion were noted. Conclusions: AS-OCT can be used to help to monitor PDS implants and potential associated complications.

Keywords: anterior segment OCT; antivascular endothelial growth factor therapy; conjunctival erosion; conjunctival retraction; implant; neovascular age-related macular degeneration; port delivery system; ranibizumab; sustained release.